Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.431
Filter
1.
J Refract Surg ; 40(6): e392-e397, 2024 May.
Article in English | MEDLINE | ID: mdl-38848056

ABSTRACT

PURPOSE: To compare the effects of corneal allogenic intrastromal ring segment (CAIRS) implantation on topographical measurements and visual outcomes of patients with keratoconus with and without corneal cross-linking (CXL) prior to the time of implantation. METHODS: Sixty-seven eyes with corneal allograft intrastromal ring segment implantation (KeraNatural; Lions VisionGift) due to advanced keratoconus were included in the study. Thirty-seven eyes had no CXL and 30 eyes had had CXL before being referred to the authors. The changes in spherical equivalent (SE), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), steep keratometry (K1), flat keratometry (K2), mean keratometry (Kmean), maximum keratometry (Kmax), and thinnest pachymetry were retrospectively analyzed 6 months after the implantation. RESULTS: The median age was 29 years in the CXL group and 24.0 years in the non-CXL group (P > .05), respectively. All topographical and visual parameters before implantation were similar in both groups (P > .05 for all parameters). At 6 months, CDVA, K1, and Kmean showed higher improvement in the non-CXL group than the CXL group (P = .030, .018, and .039, respectively). CONCLUSIONS: CAIRS surgery has a flattening effect on both the corneas with and without CXL. The cornea with prior CXL treatment had less flattening effect due to the stiffening effect of prior CXL. [J Refract Surg. 2024;40(6):e392-e397.].


Subject(s)
Collagen , Corneal Stroma , Corneal Topography , Cross-Linking Reagents , Keratoconus , Photosensitizing Agents , Prostheses and Implants , Prosthesis Implantation , Refraction, Ocular , Visual Acuity , Humans , Keratoconus/physiopathology , Keratoconus/metabolism , Keratoconus/drug therapy , Keratoconus/surgery , Corneal Stroma/metabolism , Corneal Stroma/surgery , Cross-Linking Reagents/therapeutic use , Visual Acuity/physiology , Adult , Male , Female , Photosensitizing Agents/therapeutic use , Retrospective Studies , Young Adult , Refraction, Ocular/physiology , Collagen/metabolism , Corneal Pachymetry , Riboflavin/therapeutic use , Photochemotherapy/methods , Adolescent , Ultraviolet Rays , Corneal Transplantation/methods , Middle Aged , Corneal Cross-Linking
2.
Curr Opin Ophthalmol ; 35(4): 273-277, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38700496

ABSTRACT

PURPOSE OF REVIEW: To review corneal crosslinking for keratoconus and corneal ectasia, and recent developments in the field. This study will review the mechanism of crosslinking, clinical approaches, current results, and potential future innovations. RECENT FINDINGS: Corneal crosslinking for keratoconus was first approved by U.S. FDA in 2016. Recent studies have confirmed the general long-term efficacy of the procedure in decreasing progression of keratoconus and corneal ectasia. New types of crosslinking protocols, such as transepithelial treatments, are under investigation. In addition, adjunctive procedures have been developed to improve corneal contour and visual function in these patients. SUMMARY: Crosslinking has been found to be well tolerated and effective with the goal of decreasing progression of ectatic corneal diseases, keratoconus and corneal ectasia after refractive surgery. Studies have shown its long-term efficacy. New techniques of crosslinking and adjunctive procedures may further improve treatments and results.


Subject(s)
Collagen , Cross-Linking Reagents , Keratoconus , Photochemotherapy , Photosensitizing Agents , Riboflavin , Ultraviolet Rays , Keratoconus/drug therapy , Humans , Cross-Linking Reagents/therapeutic use , Riboflavin/therapeutic use , Photosensitizing Agents/therapeutic use , Photochemotherapy/methods , Dilatation, Pathologic/drug therapy , Collagen/metabolism , Corneal Stroma/metabolism
3.
Curr Opin Ophthalmol ; 35(4): 315-321, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38700950

ABSTRACT

PURPOSE OF REVIEW: This manuscript summarizes contemporary research from 2018 to 2023 evaluating long-term (≥2 years) outcomes of corneal crosslinking (CXL) for progressive keratoconus (KCN). RECENT FINDINGS: The standard Dresden protocol (SDP) has been utilized clinically since the early 2000 s to treat ectatic disorders, primarily progressive KCN and postrefractive ectasia. Various modifications have since been introduced including accelerated and transepithelial protocols, which are aimed at improving outcomes or reducing complications. This review summarizes data demonstrating that the SDP halts disease progression and improves various visual and topographic indices (UDVA, CDVA, Kmax, K1, K2) up to 13 years postoperatively. Accelerated and transepithelial protocols have been found to be well tolerated alternatives to SDP with similar efficacy profiles. Studies focusing on pediatric populations identified overall higher progression rates after CXL. All protocols reviewed had excellent safety outcomes in adults and children. SUMMARY: Recent studies revealed that SDP successfully stabilizes KCN long term, and a variety of newer protocols are also effective. Pediatric patients may exhibit higher progression rates after CXL. Further research is required to enhance the efficacy and ease of these protocols.


Subject(s)
Collagen , Cross-Linking Reagents , Keratoconus , Photochemotherapy , Photosensitizing Agents , Riboflavin , Visual Acuity , Humans , Keratoconus/drug therapy , Keratoconus/physiopathology , Cross-Linking Reagents/therapeutic use , Photosensitizing Agents/therapeutic use , Riboflavin/therapeutic use , Photochemotherapy/methods , Collagen/therapeutic use , Visual Acuity/physiology , Ultraviolet Rays , Corneal Stroma/metabolism , Corneal Stroma/drug effects , Treatment Outcome , Corneal Topography
4.
Exp Eye Res ; 242: 109884, 2024 May.
Article in English | MEDLINE | ID: mdl-38570181

ABSTRACT

Recent studies in rabbits and case reports in humans have demonstrated the efficacy of topical losartan in the treatment of corneal scarring fibrosis after a wide range of injuries, including chemical burns, infections, surgical complications, and some diseases. It is hypothesized that the effect of losartan on the fibrotic corneal stroma occurs through a two-phase process in which losartan first triggers the elimination of myofibroblasts by directing their apoptosis via inhibition of extracellular signal-regulated kinase (ERK)-mediated signal transduction, and possibly through signaling effects on the viability and development of corneal fibroblast and fibrocyte myofibroblast precursor cells. This first step likely occurs within a week or two in most corneas with fibrosis treated with topical losartan, but the medication must be continued for much longer until the epithelial basement membrane (EBM) is fully regenerated or new myofibroblasts will develop from precursor cells. Once the myofibroblasts are eliminated from the fibrotic stroma, corneal fibroblasts can migrate into the fibrotic tissue and reabsorb/reorganize the disordered extracellular matrix (ECM) previously produced by the myofibroblasts. This second stage is longer and more variable in different eyes of rabbits and humans, and accounts for most of the variability in the time it takes for the stromal opacity to be markedly reduced by topical losartan treatment. Eventually, keratocytes reemerge in the previously fibrotic stromal tissue to fine-tune the collagens and other ECM components and maintain the normal structure of the corneal stroma. The efficacy of losartan in the prevention and treatment of corneal fibrosis suggests that it acts as a surrogate for the EBM, by suppressing TGF beta-directed scarring of the wounded corneal stroma, until control over TGF beta action is re-established by a healed EBM, while also supporting regeneration of the EBM by allowing corneal fibroblasts to occupy the subepithelial stroma in the place of myofibroblasts.


Subject(s)
Corneal Stroma , Fibrosis , Losartan , Myofibroblasts , Losartan/therapeutic use , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Stroma/pathology , Fibrosis/drug therapy , Humans , Animals , Myofibroblasts/pathology , Myofibroblasts/drug effects , Rabbits , Corneal Diseases/drug therapy , Corneal Diseases/pathology , Angiotensin II Type 1 Receptor Blockers , Administration, Topical
5.
Jpn J Ophthalmol ; 68(3): 225-232, 2024 May.
Article in English | MEDLINE | ID: mdl-38557918

ABSTRACT

PURPOSE: We aimed to compare the efficacy and safety of accelerated contact lens-assisted cross-linking (CA-CXL) with Lotrafilcon B and Comfilcon A lenses in keratoconus (KC) patients with thin corneas. STUDY DESIGN: Retrospective, single-center study. MATERIALS AND METHODS: We retrospectively included 51 eyes of 39 KC patients with corneal thickness <400µm after epithelial scraping (Epi-off), who underwent accelerated CA-CXL treatment with Lotrafilcon B (n=20) and Comfilcon A (n=31). Uncorrected and corrected distance visual acuity (UDVA and CDVA), manifest refraction values, corneal topographic data and endothelial cell density were recorded at preoperative and postoperative 1st, 3rd and 6th month controls. RESULTS: CDVA in the Comfilcon A group was higher than CDVA before surgery at 6 months postoperatively (p<0.001). When the two lenses were compared, CDVA was found to be significantly higher in the Lotrafilcon B group in the preoperative, postoperative 1st month and 3rd month values, but there was no significant difference between the postoperative 6th month values (p=0.028, p=0.018, p=0.044, p=0.181, respectively). The maximum keratometry (Kmax) value at the 6th month after surgery in the Comfilcon A group was significantly lower than in the Lotrafilcon B group (p=0,009). There was no significant difference between the endothelial cell density values between the groups (p=0.623, p=0.609, p=0.794, p=0.458, respectively). There was no significant difference between the progression, regression, and stability rates of the two groups (p=0.714). CONCLUSIONS: Accelerated CA-CXL with Lotrafilcon B and Comfilcon A silicone hydrogel lenses is a safe and effective method to stop progression in patients with thin corneas.


Subject(s)
Collagen , Corneal Topography , Cross-Linking Reagents , Keratoconus , Photochemotherapy , Photosensitizing Agents , Refraction, Ocular , Riboflavin , Visual Acuity , Humans , Keratoconus/diagnosis , Keratoconus/physiopathology , Keratoconus/drug therapy , Keratoconus/therapy , Keratoconus/metabolism , Female , Male , Retrospective Studies , Visual Acuity/physiology , Photosensitizing Agents/therapeutic use , Adult , Riboflavin/therapeutic use , Photochemotherapy/methods , Young Adult , Refraction, Ocular/physiology , Collagen/metabolism , Treatment Outcome , Cornea/pathology , Ultraviolet Rays , Follow-Up Studies , Adolescent , Cell Count , Corneal Stroma/metabolism , Endothelium, Corneal/pathology , Contact Lenses, Hydrophilic , Corneal Cross-Linking
6.
Indian J Ophthalmol ; 72(5): 712-717, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38648433

ABSTRACT

PURPOSE: To compare the changes encountered in corneal biomechanics and aberration profile following accelerated corneal collagen cross-linking (CXL) using hypo-osmolar and iso-osmolar riboflavin in corneal thicknesses of <400 and >400 microns, respectively. METHODS: This is a prospective, interventional, comparative study involving 100 eyes of 75 patients with progressive keratoconus. Eyes were divided into two groups based on corneal thickness: group 1 included eyes with a corneal thickness of <400 microns who underwent hypo-osmolar CXL, and group 2 included eyes with a corneal thickness of >400 microns who underwent iso-osmolar CXL. Corneal biomechanical and aberration profiles were evaluated and compared between groups. RESULTS: In group 1, all higher-order aberrations (HOA) except secondary astigmatism significantly decreased from baseline; however, in group 2, only coma and trefoil decreased. The corneal resistance factor and corneal hysteresis significantly improved in both groups, which was significantly greater in group 2 than in group 1. The change in inverse radius, deformation amplitude, and tomographic biomechanical index was significantly improved in group 2 as compared to group 1. CONCLUSION: Improvement in corrected distance visual acuity and decrease in HOA were significantly better in the hypo-osmolar CXL group; however, the improvement in biomechanical strength of the cornea was significantly better in the iso-osmolar group.


Subject(s)
Collagen , Cornea , Corneal Topography , Cross-Linking Reagents , Keratoconus , Photosensitizing Agents , Riboflavin , Ultraviolet Rays , Visual Acuity , Adolescent , Adult , Female , Humans , Male , Young Adult , Biomechanical Phenomena , Collagen/metabolism , Cornea/diagnostic imaging , Cornea/physiopathology , Cornea/drug effects , Corneal Stroma/metabolism , Corneal Stroma/drug effects , Corneal Wavefront Aberration/physiopathology , Cross-Linking Reagents/therapeutic use , Follow-Up Studies , Keratoconus/drug therapy , Keratoconus/physiopathology , Keratoconus/diagnosis , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Prospective Studies , Refraction, Ocular/physiology , Riboflavin/therapeutic use , Visual Acuity/physiology , Child
7.
ACS Appl Mater Interfaces ; 16(13): 15761-15772, 2024 Apr 03.
Article in English | MEDLINE | ID: mdl-38513048

ABSTRACT

Utilizing tissue-specific extracellular matrices (ECMs) is vital for replicating the composition of native tissues and developing biologically relevant biomaterials. Human- or animal-derived donor tissues and organs are the current gold standard for the source of these ECMs. To overcome the several limitations related to these ECM sources, including the highly limited availability of donor tissues, cell-derived ECM offers an alternative approach for engineering tissue-specific biomaterials, such as bioinks for three-dimensional (3D) bioprinting. 3D bioprinting is a state-of-the-art biofabrication technology that addresses the global need for donor tissues and organs. In fact, there is a vast global demand for human donor corneas that are used for treating corneal blindness, often resulting from damage in the corneal stromal microstructure. Human adipose tissue is one of the most abundant tissues and easy to access, and adipose tissue-derived stem cells (hASCs) are a highly advantageous cell type for tissue engineering. Furthermore, hASCs have already been studied in clinical trials for treating corneal stromal pathologies. In this study, a corneal stroma-specific ECM was engineered without the need for donor corneas by differentiating hASCs toward corneal stromal keratocytes (hASC-CSKs). Furthermore, this ECM was utilized as a component for corneal stroma-specific bioink where hASC-CSKs were printed to produce corneal stroma structures. This cost-effective approach combined with a clinically relevant cell type provides valuable information on developing more sustainable tissue-specific solutions and advances the field of corneal tissue engineering.


Subject(s)
Bioprinting , Tissue Engineering , Animals , Humans , Tissue Engineering/methods , Corneal Stroma/metabolism , Cornea , Extracellular Matrix/chemistry , Biocompatible Materials/metabolism , Adipose Tissue , Stem Cells , Tissue Scaffolds , Bioprinting/methods
8.
Am J Physiol Cell Physiol ; 326(5): C1482-C1493, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38525537

ABSTRACT

Corneal fibroblasts maintain homeostasis of the corneal stroma by mediating the synthesis and degradation of extracellular collagen, and these actions are promoted by transforming growth factor-ß (TGF-ß) and interleukin-1ß (IL-1ß), respectively. The cornea is densely innervated with sensory nerve fibers that are not only responsible for sensation but also required for physiological processes such as tear secretion and wound healing. Loss or dysfunction of corneal nerves thus impairs corneal epithelial wound healing and can lead to neurotrophic keratopathy. The sensory neurotransmitter substance P (SP) promotes corneal epithelial wound healing by enhancing the stimulatory effects of growth factors and fibronectin. We have now investigated the role of SP in collagen metabolism mediated by human corneal fibroblasts in culture. Although SP alone had no effect on collagen synthesis or degradation by these cells, it promoted the stimulatory effect of TGF-ß on collagen type I synthesis without affecting that of IL-1ß on the expression of matrix metalloproteinase-1. This effect of SP on TGF-ß-induced collagen synthesis was accompanied by activation of p38 mitogen-activated protein kinase (MAPK) signaling and was attenuated by pharmacological inhibition of p38 or of the neurokinin-1 receptor. Our results thus implicate SP as a modulator of TGF-ß-induced collagen type I synthesis by human corneal fibroblasts, and they suggest that loss of this function may contribute to the development of neurotrophic keratopathy.NEW & NOTEWORTHY This study investigates the role of substance P (SP) in collagen metabolism mediated by human corneal fibroblasts in culture. We found that, although SP alone had no effect on collagen synthesis or degradation by corneal fibroblasts, it promoted the stimulatory effect of transforming growth factor-ß on collagen type I synthesis without affecting that of interleukin-1ß on the expression of matrix metalloproteinase-1.


Subject(s)
Fibroblasts , Interleukin-1beta , Substance P , Transforming Growth Factor beta , p38 Mitogen-Activated Protein Kinases , Humans , Substance P/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Transforming Growth Factor beta/metabolism , Fibroblasts/metabolism , Fibroblasts/drug effects , Cells, Cultured , Interleukin-1beta/metabolism , Collagen Type I/metabolism , Collagen Type I/biosynthesis , Receptors, Neurokinin-1/metabolism , Cornea/metabolism , Cornea/drug effects , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 1/genetics , Collagen/metabolism , Collagen/biosynthesis , Signal Transduction/drug effects , Corneal Stroma/metabolism , Corneal Stroma/drug effects , Corneal Keratocytes/metabolism , Corneal Keratocytes/drug effects
9.
Cornea ; 43(5): 648-651, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38300218

ABSTRACT

PURPOSE: The aim of this study was to report a case of unilateral granular corneal dystrophy type 2 (GCD2) with exacerbation after bilateral laser in situ keratomileusis (LASIK). METHODS: Clinical evaluation, Scheimpflug imaging, anterior segment optical coherence tomography (AS-OCT), cytology, and genetic testing were used to confirm the diagnosis of unilateral GCD2 with exacerbation after bilateral LASIK. Detailed literature review for possible unilateral GCD2 presentations was performed. RESULTS: A 54-year-old White woman presented with blurred vision in her left eye and a history of bilateral LASIK performed 8 years before. Examination revealed dense opacities in the left cornea only, which were confirmed to be confined to the LASIK interface and adjacent corneal stromal tissue, as determined by AS-OCT. The patient underwent flap lift, interface debris removal, and stromal bed phototherapeutic keratectomy. Cytological analysis showed eosinophilic corneal stromal deposits that stained with trichrome stain and were congophilic on Congo red stain. Genetic testing was positive for heterozygous GCD2 transforming growth factor ß-induced gene ( TGFBI ), c.371G>A, p.R124H mutation. There were no opacities identifiable in the right eye on serial slit-lamp examination, Scheimpflug imaging, or OCT imaging at 4 or 8 years after bilateral LASIK. Literature review failed to identify any previous reports of unilateral GCD2. CONCLUSIONS: This is the first known reported case of unilateral granular corneal dystrophy type 2. LASIK is contraindicated in eyes with corneal stromal dystrophies related to mutations in TGFBI as both flap creation and laser ablation can exacerbate visually significant opacity formation. Scheimpflug and AS-OCT imaging are useful to identify opacities in GCD2.


Subject(s)
Corneal Dystrophies, Hereditary , Corneal Opacity , Keratomileusis, Laser In Situ , Humans , Female , Middle Aged , Keratomileusis, Laser In Situ/adverse effects , Corneal Dystrophies, Hereditary/etiology , Corneal Dystrophies, Hereditary/genetics , Cornea/metabolism , Corneal Stroma/metabolism , Corneal Opacity/diagnosis , Corneal Opacity/etiology , Corneal Opacity/surgery , Transforming Growth Factor beta/genetics
10.
J Cell Physiol ; 239(5): e31215, 2024 May.
Article in English | MEDLINE | ID: mdl-38308657

ABSTRACT

Primary cilia are distributed extensively within the corneal epithelium and endothelium. However, the presence of cilia in the corneal stroma and the dynamic changes and roles of endothelial and stromal cilia in corneal homeostasis remain largely unknown. Here, we present compelling evidence for the presence of primary cilia in the corneal stroma, both in vivo and in vitro. We also demonstrate dynamic changes of both endothelial and stromal cilia during corneal development. In addition, our data show that cryoinjury triggers dramatic cilium formation in the corneal endothelium and stroma. Furthermore, depletion of cilia in mutant mice lacking intraflagellar transport protein 88 compromises the corneal endothelial capacity to establish the effective tissue barrier, leading to an upregulation of α-smooth muscle actin within the corneal stroma in response to cryoinjury. These observations underscore the essential involvement of corneal endothelial and stromal cilia in maintaining corneal homeostasis and provide an innovative strategy for the treatment of corneal injuries and diseases.


Subject(s)
Cilia , Corneal Stroma , Endothelium, Corneal , Homeostasis , Animals , Mice , Actins/metabolism , Cilia/metabolism , Corneal Injuries/metabolism , Corneal Injuries/pathology , Corneal Injuries/therapy , Corneal Stroma/cytology , Corneal Stroma/growth & development , Corneal Stroma/metabolism , Endothelium, Corneal/cytology , Endothelium, Corneal/growth & development , Endothelium, Corneal/metabolism , Homeostasis/physiology , Mice, Inbred C57BL , Mice, Knockout , Tumor Suppressor Proteins/genetics , Ciliopathies/metabolism , Ciliopathies/pathology , Ciliopathies/therapy
11.
Eye (Lond) ; 38(9): 1681-1686, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38409307

ABSTRACT

OBJECTIVE: To define how estimates of keratoconus progression following collagen cross-linking (CXL) vary according to the parameter selected to measure corneal shape. MATERIALS AND METHODS: We estimated progression following CXL in 1677 eyes. We compared standard definitions of keratoconus progression based on published thresholds for Kmax, front K2, or back K2, or progression of any two of these three parameters, with the option of an increased threshold for Kmax values ≥ 55D. As corneal thickness reduces unpredictably after CXL, it was excluded from the principal analysis. We then repeated the analysis using novel adaptive estimates of progression for Kmax, front K2, or back K2, developed separately using 6463 paired readings from keratoconus eyes, with a variation of the Bland-Altman method to determine the 95% regression-based limits of agreement (LoA). We created Kaplan-Meier survival plots for both standard and adaptive thresholds. The primary outcome was progression five years after a baseline visit 9-15 months following CXL. RESULTS: Progression rates were 8% with a standard (≥ 1.5D) threshold for K2 or 6% with the static multi-parameter definition. With a ≥ 1D threshold for Kmax, the progression was significantly higher at 29%. With adaptive Kmax or K2, the progression rates were similar (20%) but less than with the adaptive multi-parameter method (22%). CONCLUSIONS: Estimates of keratoconus progression following CXL vary widely according to the reference criteria. Using adaptive thresholds (LoA) to define the repeatability of keratometry gives estimates for progression that are markedly higher than with the standard multi-parameter method.


Subject(s)
Collagen , Cornea , Corneal Topography , Cross-Linking Reagents , Disease Progression , Keratoconus , Photosensitizing Agents , Riboflavin , Keratoconus/drug therapy , Keratoconus/diagnosis , Keratoconus/physiopathology , Humans , Collagen/metabolism , Cross-Linking Reagents/therapeutic use , Male , Female , Adult , Photosensitizing Agents/therapeutic use , Riboflavin/therapeutic use , Cornea/pathology , Ultraviolet Rays , Visual Acuity/physiology , Young Adult , Photochemotherapy/methods , Corneal Pachymetry , Adolescent , Corneal Stroma/metabolism , Corneal Stroma/pathology
12.
Cornea ; 43(5): 609-626, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38289027

ABSTRACT

PURPOSE: The aims of this study were to construct a mesenchymal stem cell (MSC)-laden in situ-forming hydrogel and study its effects on preventing corneal stromal opacity. METHODS: The native gellan gum was modified by high temperature and pressure, and the rabbit bone marrow MSCs were encapsulated before adding Ca 2+ to initiate cross-linking. The effects of the hydrogel on 3D culture and gene expression of the rabbit bone marrow MSCs were observed in vitro. Then, the MSC-hydrogel was used to repair corneal stromal injury in New Zealand white rabbits within 28 days postoperation. RESULTS: The short-chain gellan gum solution has a very low viscosity (<0.1 Pa·s) that is ideal for encapsulating cells. Moreover, mRNA expressions of 3D-cultured MSCs coding for corneal stromal components (decorin, lumican, and keratocan) were upregulated (by 127.8, 165.5, and 25.4 times, respectively) ( P < 0.05) on day 21 in vitro and were verified by Western blotting results. For the in vivo study, the corneal densitometry of the experimental group was (20.73 ± 1.85) grayscale units which was lower than the other groups ( P < 0.05). The MSC-hydrogel downregulated mRNA expression coding for fibrosis markers (α-smooth muscle actin, vimentin, collagen type 5-α1, and collagen type 1-α1) in the rabbit corneal stroma. Furthermore, some of the 5-ethynyl-2'-deoxyuridine (EdU)-labeled MSCs integrated into the upper corneal stroma and expressed keratocyte-specific antigens on day 28 postoperation. CONCLUSIONS: The short-chain gellan gum allows MSCs to slowly release to the corneal stromal defect and prevent corneal stromal opacity. Some of the implanted MSCs can integrate into the corneal stroma and differentiate into keratocytes.


Subject(s)
Corneal Injuries , Corneal Opacity , Mesenchymal Stem Cells , Animals , Rabbits , Hydrogels , Cornea/metabolism , Corneal Stroma/metabolism , Corneal Keratocytes , Corneal Opacity/prevention & control , Corneal Opacity/metabolism , Corneal Injuries/metabolism , Collagen/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism
13.
Exp Eye Res ; 240: 109790, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38224848

ABSTRACT

Corneal dysfunctions associated with Diabetes Mellitus (DM), termed diabetic keratopathy (DK), can cause impaired vision and/or blindness. Hypoxia affects both Type 1 (T1DM) and Type 2 (T2DM) surprisingly, the role of hypoxia in DK is unexplored. The aim of this study was to examine the impact of hypoxia in vitro on primary human corneal stromal cells derived from Healthy (HCFs), and diabetic (T1DMs and T2DMs) subjects, by exposing them to normoxic (21% O2) or hypoxic (2% O2) conditions through 2D and 3D in vitro models. Our data revealed that hypoxia affected T2DMs by slowing their wound healing capacity, leading to significant alterations in oxidative stress-related markers, mitochondrial health, cellular homeostasis, and endoplasmic reticulum health (ER) along with fibrotic development. In T1DMs, hypoxia significantly modulated markers related to membrane permeabilization, oxidative stress via apoptotic marker (BAX), and protein degradation. Hypoxic environment induced oxidative stress (NOQ1 mediated reduction of superoxide in T1DMs and Nrf2 mediated oxidative stress in T2DMs), modulation in mitochondrial health (Heat shock protein 27 (HSP27), and dysregulation of cellular homeostasis (HSP90) in both T1DMs and T2DMs. This data underscores the significant impact of hypoxia on the diabetic cornea. Further studies are warranted to delineate the complex interactions.


Subject(s)
Corneal Diseases , Diabetes Mellitus , Humans , Corneal Stroma/metabolism , Cornea/metabolism , Corneal Diseases/etiology , Corneal Diseases/metabolism , Hypoxia/metabolism
14.
J Cataract Refract Surg ; 50(5): 523-533, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38288954

ABSTRACT

Corneal crosslinking (CXL) is used for treating keratoconus and post-laser in situ keratomileusis ectasia. However, refractive surgery is not usually performed with prophylactic CXL. Therefore, we performed a meta-analysis comparing outcomes of refractive surgeries with vs without prophylactic CXL. We systematically searched databases for studies comparing refractive surgeries for myopic correction with vs without prophylactic corneal crosslinking. Review Manager 5.4.1 was used to perform statistical analysis. We included 2820 eyes from 28 studies. Compared with refractive surgery alone, surgery with prophylactic CXL resulted in decreased central corneal thickness, corrected distance visual acuity logMAR, and safety and efficacy indices. There were no significant differences in postoperative uncorrected distance visual acuity of 20/20 or better at ≥12 months and other visual outcomes among both groups. More randomized controlled trials with standard crosslinking protocols are needed to analyze the prophylactic use of crosslinking with refractive surgeries.


Subject(s)
Collagen , Cross-Linking Reagents , Keratomileusis, Laser In Situ , Myopia , Photorefractive Keratectomy , Photosensitizing Agents , Riboflavin , Visual Acuity , Humans , Cross-Linking Reagents/therapeutic use , Photosensitizing Agents/therapeutic use , Keratomileusis, Laser In Situ/methods , Riboflavin/therapeutic use , Collagen/metabolism , Visual Acuity/physiology , Myopia/surgery , Myopia/physiopathology , Photorefractive Keratectomy/methods , Photochemotherapy/methods , Lasers, Excimer/therapeutic use , Corneal Stroma/metabolism , Corneal Stroma/surgery , Ultraviolet Rays , Keratoconus/physiopathology , Keratoconus/metabolism , Keratoconus/surgery , Keratoconus/drug therapy , Corneal Surgery, Laser/methods , Refraction, Ocular/physiology
15.
Exp Eye Res ; 239: 109794, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38237715

ABSTRACT

The purpose of this study was to evaluate transforming growth factor beta (TGFß) isoform localization in rabbit corneas with spontaneous persistent epithelial defects (PEDs) after photorefractive keratectomy (PRK). Four cryofixed corneas from a previously reported series of PEDs in rabbits that had PRK were evaluated with triplex immunohistochemistry (IHC) for TGFß3, myofibroblast marker alpha-smooth muscle actin (α-SMA) and mesenchymal marker vimentin. One cornea had sufficient remaining tissue for triplex IHC for TGFß1, TGFß2, or TGFß3 (each with α-SMA and vimentin) using isoform-specific antibodies. All three TGFß isoforms were detected in the subepithelial stroma at and surrounding the PED. Some of each TGFß isoform co-localized with α-SMA of myofibroblasts, which could be TGFß isoform autocrine production by myofibroblasts or TGFß-1, -2, and -3 binding to these myofibroblasts.


Subject(s)
Photorefractive Keratectomy , Animals , Rabbits , Vimentin/metabolism , Transforming Growth Factor beta/metabolism , Corneal Stroma/metabolism , Cornea/metabolism , Protein Isoforms/metabolism , Actins/metabolism
16.
Exp Eye Res ; 238: 109726, 2024 01.
Article in English | MEDLINE | ID: mdl-37979904

ABSTRACT

This study aimed to investigate the underlying pathophysiology of high myopia by analyzing the proteome of human corneal stromal lenticule samples obtained through small incision lenticule extraction (SMILE). A total of thirty-two patients who underwent SMILE were included in the study. Label-free quantitative proteomic analysis was performed on corneal stromal lenticule samples, equally representing high myopia (n = 10) and low myopia (n = 10) groups. The identified and profiled lenticule proteomes were analyzed using in silico tools to explore biological characteristics of differentially expressed proteins (DEPs). Additionally, LASSO regression and random forest model were employed to identify key proteins associated with the pathophysiology of high myopia. The DEPs were found to be closely linked to immune activation, extracellular matrix, and cell adhesion-related pathways according to gene ontology analysis. Specifically, decreased expression of COL1A1 and increased expression of CDH11 were associated with the pathogenesis of high myopia and validated by western blotting (n = 6) and quantitative real time polymerase chain reaction (n = 6). Overall, this study provides evidence that COL1A1 and CDH11 may contribute to the pathophysiology of high myopia based on comparative proteomic profiling of human corneal stromal lenticules obtained through SMILE.


Subject(s)
Corneal Surgery, Laser , Myopia , Humans , Proteomics , Corneal Stroma/metabolism , Myopia/metabolism , Lasers, Excimer
17.
Graefes Arch Clin Exp Ophthalmol ; 262(6): 1847-1855, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38133799

ABSTRACT

BACKGROUND: Corneal tissues indirectly obtain nutritional needs and oxygen to maintain their homeostasis, and therefore, benzalkonium chloride (BAC) containing ocular instillations for medical therapy may, in turn, induce toxic effects more than expected in corneal tissues, especially the inside stroma layer. METHODS: To evaluate the effects of very low concentrations (10-8%, 10-6%, or 10-4%) of BAC on human corneal stroma, we used two-dimensional (2D) cultures of human corneal stromal fibroblast (HCSF) cells and carried out the following analyses: (1) cell viability measurements, (2) Seahorse cellular bio-metabolism analysis, and (3) the expression of ECM molecules and endoplasmic reticulum (ER) stress-related molecules. RESULTS: In the absence and presence of 10-8%, 10-6%, or 10-4% concentrations of BAC, cell viability deteriorated and this deterioration was dose-dependent. The results showed that maximal mitochondrial respiration was decreased, the mRNA expression of most of ECM proteins was decreased, and ER stress-related molecules were substantially and dose-dependently down-regulated in HCSFs by the BAC treatment. CONCLUSIONS: The findings reported herein indicate that the presence of BAC, even at such low concentrations, is capable of causing the deterioration of cellular metabolic functions and negatively affecting the response to ER stress in HCSF cells resulting in a substantially decreased cellular viability.


Subject(s)
Benzalkonium Compounds , Cell Survival , Corneal Stroma , Preservatives, Pharmaceutical , Humans , Benzalkonium Compounds/toxicity , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Cell Survival/drug effects , Cells, Cultured , Preservatives, Pharmaceutical/toxicity , Dose-Response Relationship, Drug , Endoplasmic Reticulum Stress/drug effects , Fibroblasts/drug effects , Fibroblasts/metabolism , Corneal Keratocytes/drug effects , Corneal Keratocytes/metabolism , Real-Time Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism
18.
Indian J Ophthalmol ; 72(1): 94-97, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38131577

ABSTRACT

PURPOSE: To assess the long-term safety and stability of visual outcomes following the modified technique of collagen crosslinking (CXL) using refractive lenticule in eyes with thin corneas (<400 µm) and progressive keratoconus. SETTING: A tertiary eye care hospital in India. DESIGN: Prospective, interventional case series. METHODS: Eyes with progressive keratoconus and thin corneas (<400 µm) underwent CXL with intraoperative stromal augmentation using a refractive lenticule obtained from small-incision lenticule extraction (SMILE). Preoperative and postoperative evaluation (3 months, and then yearly thereafter) included corneal tomography (Oculus Pentacam), uncorrected and corrected distance visual acuity (UDVA and CDVA, respectively), manifest refraction, and endothelial cell count (specular microscopy), and adverse events, if any, were noted. The patients were followed up for a period of 5 years. RESULTS: Seven eyes were included in the analysis. Mean corneal flattening of -4.29 D was noted from preoperative maximum keratometry (P = 0.018). An improvement in UDVA and CDVA of 0.38 logarithm of minimum angle of resolution (logMAR) and 0.36 logMAR, respectively, was noted at 5 years postoperative visit. Four eyes demonstrated a gain of two lines in CDVA. Mean spherical equivalent improved from -6.85 D preoperatively to -6.05 D at 5 years postoperatively. Clear demarcation line was noted between 230 to 270 µm on anterior segment optical coherence topography. No significant endothelial cell loss was noted postoperatively. CONCLUSION: Long-term outcomes demonstrated safety and disease stability following lenticule-assisted CXL.


Subject(s)
Keratoconus , Humans , Keratoconus/diagnosis , Keratoconus/drug therapy , Keratoconus/surgery , Prospective Studies , Corneal Stroma/surgery , Corneal Stroma/metabolism , Photosensitizing Agents/therapeutic use , Riboflavin/therapeutic use , Corneal Topography , Cornea/surgery , Cornea/metabolism , Cross-Linking Reagents/pharmacology , Cross-Linking Reagents/therapeutic use
19.
J Proteome Res ; 22(12): 3730-3741, 2023 12 01.
Article in English | MEDLINE | ID: mdl-37976471

ABSTRACT

Cornea transplantation is one of the most commonly performed allotransplantations worldwide. Prolonged storage of donor corneas leads to decreased endothelial cell viability, severe stromal edema, and opacification, significantly compromising the success rate of corneal transplantation. Corneal stroma, which constitutes the majority of the cornea, plays a crucial role in maintaining its shape and transparency. In this study, we conducted proteomic analysis of corneal stroma preserved in Optisol-GS medium at 4 °C for 7 or 14 days to investigate molecular changes during storage. Among 1923 identified proteins, 1634 were quantifiable and 387 were significantly regulated with longer preservation. Compared to stroma preserved for 7 days, proteins involved in ocular surface immunomodulation were largely downregulated while proteins associated with extracellular matrix reorganization and fibrosis were upregulated in those preserved for 14 days. The increase in extracellular matrix structural proteins together with upregulation of growth factor signaling implies the occurrence of stromal fibrosis, which may compromise tissue clarity and cause vision impairments. This study is the first to provide insights into how storage duration affects corneal stroma from a proteomic perspective. Our findings may contribute to future research efforts aimed at developing long-term preservation techniques and improving the quality of preserved corneas, thus maximizing their clinical application.


Subject(s)
Cryopreservation , Proteomics , Humans , Cryopreservation/methods , Cornea , Corneal Stroma/metabolism , Extracellular Matrix , Gentamicins/metabolism , Complex Mixtures/metabolism
20.
Exp Eye Res ; 237: 109717, 2023 12.
Article in English | MEDLINE | ID: mdl-37944849

ABSTRACT

Prolonged hyperglycemia during diabetes mellitus (DM) is associated with severe complications that may affect both the anterior and posterior ocular segments, leading to impaired vision or blindness. The cornea is a vital part of the eye that has a dual role as a protective transparent barrier and as a major refractive structure and is likewise negatively affected by hyperglycemia in DM. Understanding the cellular and molecular mechanisms underlying the phenotypic changes associated with DM is critical to developing targeted therapies to promote tissue integrity. In this proof-of-concept study, we applied a cell sheet-based approach to generate stacked constructs of physiological corneal thickness using primary human corneal fibroblasts isolated from cadaveric control (healthy), Type 1 DM and Type 2 DM corneal tissues. Self-assembled corneal stromal sheets were generated after 2 weeks in culture, isolated, and subsequently assembled to create stacked constructs, which were evaluated using transmission electron microscopy. Analysis of gene expression patterns revealed significant downregulation of fibrotic markers, α-smooth muscle actin, and collagen type 3, with stacking in Type 2 DM constructs when compared to controls. IGF1 expression was significantly upregulated in Type 2 DM constructs compared to controls with a significant reduction induced by stacking. This study describes the development of a thicker, self-assembled corneal stromal construct as a platform to evaluate phenotypic differences associated with DM-derived corneal fibroblasts and enable the development of targeted therapeutics to promote corneal integrity.


Subject(s)
Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Hyperglycemia , Humans , Corneal Stroma/metabolism , Cornea , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 1/metabolism , Hyperglycemia/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...